Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13073061 | 0.98 | CHRM2 (1.00) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| Bromide SCHEMBL9147626 | 0.94 | CHRM2 (0.88) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| Bromide SCHEMBL7141283 | 0.89 | CHRM2 (0.80) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL12802521 | 0.87 | CHRM2 (0.79) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL9151027 | 0.87 | CHRM2 (0.78) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL12802779 | 0.87 | CHRM2 (0.79) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| Hydrochloric Acid SCHEMBL6691235 | 0.86 | CHRM2 (0.76) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| Hydrochloric Acid SCHEMBL6685326 | 0.86 | CHRM2 (0.76) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| Hydrochloric Acid SCHEMBL6685837 | 0.86 | CHRM2 (0.76) | CHRM2MEN1CYP1A2CYP2C19KMT2A | |
| SCHEMBL2196672 | 0.84 | CHRM2 (0.75) | CHRM2MEN1CYP1A2CYP2C19KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107349-A1 | Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | US | claimed |
| US-20220193169-A1 | ANTI-INFLAMMATORY COMPOSITION | FERMENTATIONEXPERTS A/S (DK) | 2022-06-23 | — | — | US | disclosed |
| WO-2009060203-A1 | 3,4,6,7-TETRAHYDRO-1 H-PYRROLO[3,4-D]PYRIMIDINE-2,5-DIONES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2009-05-14 | — | — | WO | disclosed |
| WO-2007029063-A2 | TREATMENT AND/OR PREVENTION OF PERVASIVE DEVELOPMENTAL DISORDERS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2007-03-15 | — | — | WO | disclosed |
| US-20050107349-A1 | Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith | PHARMACIA CORPORATION (US) | 2005-05-19 | — | — | US | disclosed |
| WO-2005009340-A2 | METHOD FOR THE TREATMENT OR PREVENTION OF RESPIRATORY DISORDERS WITH A CYCLOOXYGENASE-2 INHIBITOR IN COMBINATION WITH A MUSCARINIC RECEPTOR ANTAGONIST AND COMPOSITIONS THEREWITH | PHARMACIA CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2002072025-A2 | IMPROVING POSTSYNAPTIC RESPONSE BY A COMBINATION OF 4-MINOPYRIDINE AND AGONIST | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107349-A1 | Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith | CHRM3, CYSLTR2, CHRM2 | CHRM2 3/4885MEN1 4278/4885CYP1A2 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.